Wa'el Hashad
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
October 09, 2024 09:05 ET | Longeveron
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.
Longeveron Logo.jpg
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
October 07, 2024 09:05 ET | Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Longeveron Logo.jpg
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 02, 2024 09:05 ET | Longeveron
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Longeveron Logo.jpg
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 26, 2024 09:05 ET | Longeveron
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Wa'el Hashad
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
September 03, 2024 09:00 ET | Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
Wa'el Hashad
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:05 ET | Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Nataliya Agafonova
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
July 28, 2024 16:51 ET | Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Wa'el Hashad
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
July 17, 2024 08:00 ET | Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Roger Hajjar_Ring_6483 - Cropped Headshot
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
July 08, 2024 09:00 ET | Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Longeveron Logo.jpg
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET | Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.